Connection

David Cole to Immunotherapy, Adoptive

This is a "connection" page, showing publications David Cole has written about Immunotherapy, Adoptive.
Connection Strength

1.056
  1. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
    View in: PubMed
    Score: 0.350
  2. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
    View in: PubMed
    Score: 0.109
  3. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
    View in: PubMed
    Score: 0.107
  4. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1994 May; 38(5):299-303.
    View in: PubMed
    Score: 0.102
  5. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol. 2012 Aug 15; 189(4):1627-38.
    View in: PubMed
    Score: 0.090
  6. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009 Feb 15; 182(4):2030-40.
    View in: PubMed
    Score: 0.071
  7. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother. 2008 Apr; 57(4):563-72.
    View in: PubMed
    Score: 0.064
  8. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
    View in: PubMed
    Score: 0.061
  9. Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. Cancer Treat Rev. 2019 Jul; 77:35-43.
    View in: PubMed
    Score: 0.036
  10. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
    View in: PubMed
    Score: 0.034
  11. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.